ERBB2 and neoplasm: The potencies for tumor cell killing of the eSrtA-conjugated maytansinoid-based ADCs were evaluated and compared to commercially available Kadcyla using the HER-2 overexpressing breast cancer cell line SKBR3 and, as a control, the breast cancer cell line T47D expressing low to moderate levels of HER-2 (Fig 4).